Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer

Pia Bükmann Larsen; Maja Jørgensen; Lennart Friis-Hansen; Steen Ingeberg

doi:10.1002/ccr3.411

Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer

Clin Case Rep. 2015 Oct 29;3(12):987-9. doi: 10.1002/ccr3.411. eCollection 2015 Dec.

Authors

Pia Bükmann Larsen¹, Maja Jørgensen¹, Lennart Friis-Hansen¹, Steen Ingeberg²

Affiliations

¹ Department of Clinical Biochemistry Næstved Hospital Næstved Denmark.
² Department of Clinical Oncology Næstved Hospital Næstved Denmark.

Abstract

Heparin-induced thrombocytopenia (HIT) is a serious adverse reaction to heparin treatment with a high risk of thrombosis. Heparin must be discontinued immediately and replaced with alternative anticoagulants that do not interact with HIT antibodies. In this case, a lung cancer patient, diagnosed with HIT was successfully treated with apixaban.

Keywords: Apixaban; cancer; dalteparin; heparin‐induced thrombocytopenia.

Publication types

Case Reports